DM Kent, DE Thaler - The New England Journal of Medicine, 2008 - nejm.highwire.org If clinical trials were sporting contests, then it would be fair to say that
low-dose aspirin plus ex- tended-release dipyridamole (Aggrenox) was the clear
favorite against clopidogrel going into the Prevention Regimen for ... Cited by 9 - Related articles - All 5 versions
D Mauri, NP Polyzos, G Salanti, N Pavlidis, J … - JNCI Journal of the National Cancer Institute, 2008 - jnci.oxfordjournals.org Methods: We performed a systematic review of all trials that compared different
regimens involving chemotherapy and/or targeted therapy in advanced breast
cancer (1973–2007). Regimens were categorized a priori into different ... Cited by 6 - Related articles - All 10 versions
EJ Mills, B Rachlis, C O'Regan, L Thabane, D … - BMC cancer, 2009 - biomedcentral.com We included 3 bevacizumab (2 of bevacizumab plus interferon-a [IFN-a]), 2
sorafenib, 1 sunitinib, and 1 temsirolimus trials (total n = 3,957). All
interventions offer advantages for PFS. Using indirect comparisons with ... Cited by 7 - Related articles - Cached - All 7 versions
JPA Ioannidis - Bulletin of the NYU Hospital for Joint Diseases, 2008 - nyuhjdbulletin.org Abstract Randomized trials are an excellent research design with major
advantages. However, randomized trials are not im- mune to biases, and
inferences from them may be sometimes flawed or irrelevant. The present ... Cited by 1 - Related articles - View as HTML - All 2 versions
AP Chiang, AJ Butte - Clinical Pharmacology & Therapeutics, 2009 - nature.com Drug repositioning refers to the discovery of alternative uses for drugs—uses
that are different from that for which the drugs were originally intended. One
challenge in this effort lies in choosing the indication for which a drug ... Related articles - All 3 versions
EJ Mills, P Wu, D Spurden, JO Ebbert, K … - Harm Reduction Journal, 2009 - pubmedcentral.nih.gov We searched 10 electronic medical databases (inception to October 2008). We
selected randomized clinical trials [RCTs] evaluating interventions for our
primary outcome of abstinence from smoking at at-least 4 weeks post-target ... Related articles - All 8 versions
J Ioannidis - Canadian Medical Association Journal, 2009 - ecmaj.ca Given this complexity, one has to consider what alternative treatments are
available and what their effects are on various beneficial and harmful outcomes.
One should see how the various alternatives have been compared against no ... Cited by 1 - Related articles - All 11 versions
C O'Regan, I Ghement, O Eyawo, GH Guyatt, … - Trials, 2009 - pubmedcentral.nih.gov Comparing the effectiveness of interventions is now a requirement for regulatory
approval in several countries. It also aids in clinical and public health
decision-making. However, in the absence of head-to-head randomized trials ... Related articles - All 7 versions
L Manzoli, G Salanti, C De Vito, A Boccia, JPA … - The Lancet Infectious Diseases, 2009 - Elsevier Influenza H5N1 is thought to be a likely causative agent for a future human
influenza pandemic. Several types of H5N1 vaccine have been tested, including
different doses and adjuvants, and a meta-analysis is needed to identify ... Cited by 1 - Related articles - All 22 versions
B Schöttker, D Lühmann, D Boulkhemair, H … - gripsdb.dimdi.de Die HTA-Berichte des DIMDI durchlaufen ein unabhängiges, grundsätzlich
anonymisiertes Gutachter- verfahren. Potentielle Interessenkonflikte bezüglich
der HTA-Berichte werden dem DIMDI von den Autoren und den Gutachtern ... Related articles - All 2 versions